Syntex EC-Naprosyrn
Executive Summary
Enteric-coated naproxen delayed-release tablets receive clearance on Oct. 14. The prescription NSAID, indicated for treating pain and inflammation associated with osteoarthritis and rheumatoid arthritis, will be available in 375 mg and 500 mg strengths for twice-daily dosing in early 1995, the company says